ストックスクリーナーアプリを入手
26.50
7.99%
-2.345
アフターアワーズ：
26.50
前日終値:
$28.84
開ける：
$27.39
24時間の取引高:
47,267
Relative Volume:
1.62
時価総額：
$26.95M
収益：
-
当期純損益:
$-33.04M
株価収益率:
-2.9114
EPS:
-9.1023
ネットキャッシュフロー:
$-39.66M
1週間 パフォーマンス:
-12.45%
1か月 パフォーマンス:
-22.03%
6か月 パフォーマンス:
+27.60%
1年 パフォーマンス:
-91.81%
1日の値動き範囲:
$25.77
$28.50
1週間の範囲:
$25.77
$30.44
52週間の値動き範囲:
$15.10
$909.98
Quince Therapeutics Inc Stock (QNCX) Company Profile
名前
Quince Therapeutics Inc
セクター
電話
415-910-5717
住所
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
26.50 | 30.05M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
513.35 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
774.83 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
985.16 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.65 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
195.92 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-08-05 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-03-24 | 開始されました | Oppenheimer | Outperform |
Quince Therapeutics Inc (QNCX) 最新ニュース
Quince Therapeutics at Cantor conference: inhaled rapamycin gains traction By Investing.com - Investing.com South Africa
Quince Therapeutics forms Scientific Advisory Board to advance LAM-001 - scanx.trade
Quince Therapeutics Faces Nasdaq Listing Compliance Challenges - The Globe and Mail
Should I Buy QNCX? QNCX 2026 AnalysisIntellectia AI™ - Intellectia AI
Quince Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Quince Therapeutics to Participate in September 2026 Investor Conferences - Quiver Quantitative
$Quince Therapeutics (QNCX.US)$ - Moomoo
QNCX stock holds steady as Quince Therapeutics pursues strategic alternatives - ad-hoc-news.de
Quince Therapeutics Announces Planned Presidential Leadership Transition - The Globe and Mail
Quince Therapeutics' Charles Ryan to Depart as President, Last Day Sept 8, 2026 - TradingView
Quince Therapeutics, Inc. Announces Resignation of Charles Ryan from President, Effective September 8, 2026 - marketscreener.com
Quince Therapeutics, Inc. SEC Filing (Aug 25, 2026) | QNCX EFFECT - Stock Titan
Quince (QNCX) Results at a Glance: The Available Earnings Metric Delivers a Beat; Market Move: Shares Finish 7.12% Lower in the Available RecordEarnings Seasonality - vinanet.vn
Balyasny Asset Management L.P. Initiates New Position in Quince Therapeutics Inc (QNCX) - GuruFocus
Craig-Hallum Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $68 - Moomoo
Quince (QNCX) Chart: Slides 0.90% to $34.26 at the Close; Price Setup: Price Remains Between $32.55 Support and $35.97 Resistance in the Available RecordSentiment Divergence - vinanet.vn
Craig-Hallum Initiates Coverage on Quince Therapeutics (QNCX) wi - GuruFocus
Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Addus Homecare (ADUS) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
LifeSci Capital Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Cuts Target Price to $98 - Moomoo
Quince Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
QNCX Reiterated by Cantor Fitzgerald -- Price Target Maintained at $70 - gurufocus.com
Quince Plans Shareholder Vote on Major Stock Issuance - The Globe and Mail
Form 8K Quince Therapeutics Inc For: 17 August By Investing.com - Investing.com Nigeria
Quince Therapeutics Closes Orphai Acquisition With $115M PIPE Financing - Minichart
Quince Therapeutics plans special meeting to vote on share issuance and potential change of control - Investing.com
Quince Therapeutics to seek shareholder OK for Series C conversion, adding ~11M shares and reclassifying $6.3M warrants - TradingView
Ikarian Capital discloses 9.0% Quince Therapeutics (QNCX) ownership in Schedule 13G - Stock Titan
Nantahala Capital (QNCX) reports 0% stake in Quince Therapeutics in latest 13G/A - Stock Titan
Quince Therapeutics (QNCX) Jumps 5% to $34.04 as Bulls Target $35.74 ResistanceBlue Chip Entry Points - vinanet.vn
Quince Therapeutics (QNCX) books $39.6M loss but lifts cash to $116M - Stock Titan
Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Quince Therapeutics, Inc. (NASDAQ: QNCX) Stock Price, News & Analysis - Kalkine
Quince Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Cormorant Asset Management (QNCX) reports 9.99% Quince Therapeutics stake via convertibles - Stock Titan
Quince Therapeutics Q2 EPS of $(12.31) beats $(26.32) estimate - scanx.trade
Quince Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Quince Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update - TradingView
Quince Reports $75.5 Million Second Quarter Net Loss After Orphai Deal - Quiver Quantitative
QNCX: Orphai acquisition, $115M financing, and LAM-001 trial progress define a pivotal Q2 2026 - TradingView
Quince Therapeutics reports $75.5M Q2 net loss, $116M cash as of June 30, 2026 - TradingView
Quince Therapeutics Q2 net loss widens on acquisition charges - TradingView
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update - The Manila Times
Quince Adds Inhaled Rapamycin Program for Pulmonary Diseases - Stock Titan
Quince Therapeutics (QNCX): Balyasny group discloses 9.99% beneficial stake cap - Stock Titan
Quince Therapeutics (QNCX) Pushes Higher, Up 3.68% as Shares Test Key Resistance at $34.03Iron Condor Alert - Vinanet
QNCX Q2'26 Earnings: EPS estimate is (28.02) USD - TradingView
Quince Therapeutics, Inc. expected to post a loss of $17.88 a shareEarnings Preview - TradingView
Quince Therapeutics (QNCX) updates S-3 shelf with legal opinion and $498K in costs - Stock Titan
Quince Therapeutics (QNCX) sees Squadron group report 5.6% ownership stake - Stock Titan
Quince Therapeutics Inc (QNCX) 財務データ
収益
当期純利益
現金流量
EPS
Quince Therapeutics Inc (QNCX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
0.23%
2.40%
大文字化:
|
ボリューム (24 時間):